Stock Pulse
AbbVie (ABBV) demonstrated strong 2024 revenue growth driven by non-Humira products, particularly Skyrizi and Rinvoq, offsetting Humira's patent loss [11]. The company continues to invest in R&D, evidenced by a new partnership with AbCellera for T-cell engager technology [10], and has increased its dividend for the 12th consecutive year [6]. While facing increased competition in the obesity drug market from companies like Roche and Viking Therapeutics [4], [5], AbbVie's growth platform and diversification strategy suggest positive long-term prospects [3], [9]. Recent stock performance has been positive, outperforming the S&P 500 [1], but multiple insider stock sales by company officers have also been reported [12], [13], [14], [15]. Near-term performance is expected to be in line with the market, with a Zacks Rank of #3 (Hold) [1].